The decrease in CarnoSyn ® beta-alanine royalty, licensing, and raw material sales revenue during the second quarter of fiscal 2025 was primarily due to a decrease in orders from existing customers.

However, revenue from CarnoSyn® beta-alanine declined by 18%. For the six months ending December 31, total sales rose by 14% to $67.2 million, even as the company experienced a loss of $4.2 ...

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 18% to $1.8 million during the second quarter of fiscal year 2025, as compared to $2.2 million for the second ...